



Fig. 1
May 2007

Retention Sites Following Product Use

	Lawlor Lozenge (Ex. 8)	Eclipse gum	BreathSavers
5 min	0.0	0.0	0.0
10 min	0.0	0.0	0.0
20 min	0.0	0.0	0.0
30 min	0.0	0.0	0.0

Fig. 2 May 2007




Fig. 3

September 2003 Mean Retention Sites/Product

Sample and Percent CaCO ₃	Treatment	# Retention Sites (mean)		
		5 min	15 min	30 min
A – 46.9%	CaCO ₃	6.6	5.4	4.8
B – 37.8%	CaCO ₃ + HEC/CMC(3/6%) + NaHCO ₃	12.8	10.7	6
C – 39.1%	CaCO ₃ + Sorbitol	4.4	3.4	2.6

Fig. 4

Product A - CaCO_3




Fig. 5

Product B – CaCO_3 + HEC/CMC(3/6%) + NaHCO_3





Fig. 6

Product C – CaCO_3 + Sorbitol



6




4



4

#4 N/A




3




5


5 min.



5




4



2



2




4

15 min.



3



4



2



2



2

30 min.